

参考文献

- Martinez E. The NEFA study: Results at three years. *AIDS Rev.* 2007; 9:62.
- McGovern RA, Thielen A, Mo T, et al. Population-based V3 genotypic tropism assay: A retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. *AIDS.* 2010;24:2517-25.
- Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from a tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. *Lancet Infect Dis.* 2016 Jan;16(1):43-52.
- Mills AM, Cohen C, Dejesus E, et al. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. *HIV Clin Trials.* 2013;14(5):216-223.
- Molina JM, Ward D, Brar I, et al. Switching to fixed-dose bicitgravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. *Lancet HIV.* 2018 Jul;5(7):e357-e365.
- Nichols G, Lazzarin A, Maggiolo F, et al. Phase III assessment of dolutegravir (DTG) 50 mg twice daily (BID) in HIV-1 infected subjects with raltegravir (RAL) and/or elvitegravir (EVG) resistance in VIKING-3: Week 24 results of all 183 subjects enrolled. IAS 2013, Kuala Lumpur, Malaysia. Poster TULBPE19.
- Orkin C, Arastéh K, Hernández-Mora MG, et al. Long-Acting Cabotegravir and Rilpivirine After Oral Induction for HIV-1 Infection. *N Engl J Med.* 2020 Mar 19;382(12):1124-1135.
- Orkin C, Arastéh K, Hernández-Mora MG, et al. Long-acting cabotegravir + rilpivirine for HIV maintenance: FLAIR week 48 results. 2019 CROI. March 4-7, 2019. Seattle, WA. Abstract 140.
- Orkin C, DeJesus E, Ramgopal M, et al. Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Coformulated With Rilpivirine and Emtricitabine in Virologically Suppressed Adults With HIV-1 Infection: A Randomised, Double-Blind, Multicentre, Phase 3b, Non-Inferiority Study. *Lancet HIV.* 2017 May;4(5):e195-e204.
- Orkin C, Molina J-M, Negredo E, et al. Efficacy and Safety of Switching From Boosted Protease Inhibitors Plus Emtricitabine and Tenofovir Disoproxil Fumarate Regimens to Single-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide at 48 Weeks in Adults With Virologically Suppressed HIV-1 (EMERALD): A Phase 3, Randomised, Non-Inferiority Trial. *Lancet HIV.* 2018 Jan;5(1):e23-e34.